Strategic partnerships Prevencio is actively engaging with healthcare institutions and health networks (Seattle Children's; Quadrant Health) to embed its HART tests into existing care pathways, signaling clear sales opportunities in integrated primary care and hospital systems.

AI driven differentiation The company emphasizes AI-powered multi-protein blood tests that outperform standard biomarkers and risk scores, presenting a compelling value proposition for health systems pursuing precision medicine, risk stratification, and preventative cardio care.

Specialty test portfolio Prevencio has a diversified, patented test slate (HART PAD, HART CADhs, HART CVE, etc.) with ongoing development, offering multiple entry points across cardiovascular disease, peripheral artery disease, and pediatric Kawasaki disease testing.

Clinical validation Presence in top-tier cardiology journals and presentations at major cardiovascular meetings supports clinical credibility, aiding sales conversations with clinicians, procurement, and hospital committees seeking validated diagnostics.

Growth signals Recent announcements of ESC Congress data presentations and partnerships indicate momentum and market visibility, suggesting opportunities to leverage conferences and co-marketing to accelerate adoption among health systems and payers.